Navigation Links
Mylan Receives Approval for Generic Version of Zinecard® for Injection
Date:11/28/2011

PITTSBURGH, Nov. 28, 2011 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its business Mylan Institutional has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Dexrazoxane for Injection, packaged in 250 mg and 500 mg Single-use Vials. This product is the generic version of Pharmacia & Upjohn's Zinecard® for Injection, a chemoprotective agent.

Dexrazoxane for Injection, when indicated for the same use as Zinecard for Injection, had U.S. sales of approximately $3.4 million for the 12 months ending Sept. 30, 2011, according to IMS Health. Mylan Institutional is shipping this product immediately.   

Currently, Mylan has 161 ANDAs pending FDA approval representing $97.7 billion in annual sales, according to IMS Health. Forty-three of these pending ANDAs are potential first-to-file opportunities, representing $26.9 billion in annual brand sales, for the 12 months ending June 30, 2011, according to IMS Health.

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 150 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information about Mylan, please visit http://www.mylan.com/. For more information about generic drugs, please visit http://www.choosinggenerics.com/.

 

 

 

 

 

 

 


'/>"/>
SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Mylan Announces Settlement Agreement Related to Antidepressant Effexor XR(R)
2. Mylan Receives FDA Approval for Generic Version of Parkinsons Treatment Sinemet(R)
3. Mylan Schedules Third Quarter 2009 Financial Results Conference Call and Live Webcast
4. Mylan Receives FDA Approval for Generic Version of Anticonvulsant Topamax(R) Sprinkle Capsules
5. Mylan Confirms First-to-File Patent Challenge Relating to Caduet(R)
6. Mylan Receives Approval for Generic Version of GoLytely(R)
7. Mylan Declares Quarterly Preferred Stock Dividend
8. Mylan Pre-Pays All Scheduled 2011 Term-Loan Borrowings
9. Mylan Confirms First-to-File Patent Challenge Relating to Vytorin(R) Cholesterol Medication
10. Mylans President of Europe, Middle East and Africa Elected President of European Generic Medicines Association
11. Mylan Receives Tentative FDA Approval Under PEPFAR for Matrix Laboratories New Drug Application (NDA) for Efavirenz Tablets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... , March 27, 2017  Cryoport, Inc. (NASDAQ: CYRX, ... intends to offer shares of common stock in an ... on file with the Securities and Exchange Commission (the ... conditions, and there can be no assurance as to ... as to the actual size or terms of the ...
(Date:3/27/2017)... 27, 2017  A new survey from ... Medicare,s Competitive Bidding Program (CBP) significantly reduced beneficiary choice ... lack of choice forces beneficiaries to switch to unfamiliar ... consequences. AADE,s survey is the latest ... others pointing out the inherent problems with the CBP. ...
(Date:3/27/2017)... March 27, 2017 /PRNewswire/ - INVICTUS MD STRATEGIES CORP. ... 8IS) Invictus MD is pleased to announce it has ... trading on the TSX Venture Exchange.  ... a year of significant achievements for Invictus-MD. Some of ... crops at AB Laboratories Inc. ("AB Labs"), a Licensed ...
Breaking Medicine Technology:
(Date:3/27/2017)... ... March 27, 2017 , ... American ... conference coverage on veterinary medicine, announces the launch of Veterinarian’s Money Digest™, a ... with the April edition of American Veterinarian™. , “We look forward ...
(Date:3/27/2017)... , ... March 27, 2017 , ... ... research products enables researchers to pursue the recent RNA methylation “gold rush” with ... In light of the newfound characteristics of N6-methyladenosine, or m6A , RNA ...
(Date:3/27/2017)... , ... March 27, 2017 , ... According to the ... cancer, including all stages, is more than 95%. Once the cancer spreads to other ... than 30%. To find out how to avoid this latter group, tune in to ...
(Date:3/27/2017)... ... March 27, 2017 , ... ?Grow Healthy Vending LLC announced ... litigation between itself and 1800 Vending DBA Healthy You Vending. (Civil No. 1:14-CV-00121-CW/ ... to announce that we have now reached a settlement agreement regarding the ongoing ...
(Date:3/27/2017)... HOUSTON, Texas (PRWEB) , ... March 27, 2017 , ... ... and hard of hearing, is bringing its latest products to the Deaf Seniors of ... attendees will have the opportunity to meet with knowledgeable ASL friendly staff from Harris ...
Breaking Medicine News(10 mins):